Dr Kai Keen Shiu

Dr Shiu is a trials and research active Consultant in the Gastrointestinal Oncology Unit at University College London Hospital NHS Foundation Trust and Honorary Associate Professor at the UCL Cancer Institute.

He qualified at Guys and St Thomas’ Medical School, training in medical oncology at the Royal Free Hospital and UCLH. He completed his PhD in integrative genomic profiling of cancer at the Institute of Cancer Research and the Royal Marsden Hospital with Alan Ashworth. He also attained a post CCT research fellowship at the MRC Clinical Trials Unit at UCL. He is a Fellow of the Royal College of Physicians, London, and member of ASCO, ESMO and the Association of Cancer Physicians UK.

Dr Shiu is the UK Chief Investigator or Principal Investigator for several GI immuno-oncology trials including KEYNOTE 811 and 859, VESTIGE, MATTERHORN,  KEYNOTE 177, LEAP 17, MK4280A-007, MK-1308A-008, BNT122-01, NOUS-209-01, and Chief Investigator of the NEOPRISM-CRC; an investigator-initiated trial of neoadjuvant immunotherapy. He is also the UK Chief Investigator for CUPISCO, a 1st line Phase 2 randomised molecular guided therapy CUP trial.

His translational research interests include immunotherapy for GI malignancies and Cancer of Unknown Primary. He is Chair of the NCRI MUO-CUP Workstream and a member of the NCRI Colorectal Advanced and Adjuvant Disease Subgroup. He is a collaborator in the PEACE (Posthumous tissuE donAtion in CancEr) study, and a member of the Gastrointestinal Oncology and CUP subgroups at UCL Cancer Institute/Francis Crick Institute. He is the Principal Investigator of the UCL/UCLH Gastrointestinal Cancer Translational Research Biobank.